Biomarker ID | 589 |
PMID | 21305254 |
Year | 2011 |
Biomarker | Albumin (ALB); Rho GDP dissociation inhibitor (GDI) α (ARHGDIA); Keratin 18 (KRT18); Keratin 19 (KRT19); Keratin 8 (KRT8); |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Tissue |
Subjects | Humans |
Regulation | Downregulated in Gleason Score 7(Fold Change) : Albumin (ALB) [2.155]; Rho GDP dissociation inhibitor (GDI) α (ARHGDIA) [2.571]; Keratin 18 (KRT18) [3.322]; Keratin 19 (KRT19) [4.950]; Keratin 8 (KRT8) [4.950]; |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways Include(ALB):- HDL-mediated lipid transport,Transport of vitamins, nucleosides, and related molecules,Transport of organic anions,Folate metabolism,Vitamin B12 metabolism Pathways Include(GDI):-Membrane Trafficking,RAB GEFs exchange GTP for GDP on RABs,Rho GTPase cycle,Signal Transduction,Signaling by Rho GTPases,Vesicle-mediated transport |
Experiment | Gleason Score 5 Vs Gleason Score 7 |
Type of Biomarker | Prognostic |
Cohort | Samples from 16 patients diagnosed with BPH along woth 8 patients with prostate cancer were chosen. 4 had Gleason Score 7 and 4 had Gleason Score 5. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | MALDI-TOF-MS |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | ALB, GDI, ARHGDIA, KRT18, KRT19, KRT8 |